clinical trial · NCT04636814
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Chiesi Farmaceutici S.p.A.·phase3·terminated·n = 3,973
Chronic Obstructive Pulmonary DiseaseCHF6001 1600µgCHF6001 3200µgPlaceboRoflumilast
brief summary
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
started
Jul 12, 2021
primary completion
Dec 23, 2025
completion
Dec 23, 2025
last updated
Feb 2, 2026
official title
A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol